Understanding how lung cancer affects COVID-19 vulnerability
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses
This study is looking at how lung cancer affects patients' ability to fight off COVID-19 and how well vaccines work for them, so we can find better ways to keep lung cancer patients safe from the virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10688370 on NIH RePORTER |
What this research studies
This research investigates why lung cancer patients are more vulnerable to severe outcomes from COVID-19 by analyzing their antibody responses to the virus. It compares the immune responses of lung cancer patients to those without lung cancer, focusing on how well their bodies can fight off the virus and the effectiveness of vaccines. The study will also examine how different lung cancer characteristics and treatments might influence these immune responses. By understanding these factors, the research aims to develop better protection strategies for lung cancer patients against COVID-19.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with lung cancer who may be at increased risk for severe COVID-19.
Not a fit: Patients without lung cancer or those who are not at risk for severe COVID-19 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccination strategies and treatments specifically tailored for lung cancer patients to protect them from severe COVID-19 outcomes.
How similar studies have performed: Other research has shown that understanding immune responses in cancer patients can lead to significant advancements in treatment and protection strategies, indicating a promising approach in this area.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Hirsch, Fred R — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hirsch, Fred R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.